PT  - JOURNAL ARTICLE
AU  - Kavita Dave
AU  - Fauzia Imam
AU  - Nora Mayer
AU  - Nizar Asadi
AU  - Martin Carby
AU  - Anna Reed
AU  - Vicky Gerovasili
TI  - Single centre lung transplant experience of customised biodegradable stents in the early post-lung transplant period
AID  - 10.1183/13993003.congress-2021.PA3496
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - PA3496
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/PA3496.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/PA3496.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: Airway complications after Lung Transplantation(LTx) include bronchial stenoses which require balloon dilatations and stenting and cause complications such as infection and granulation tissue. Biodegradable stents may provide a safer alternative.Aims: To describe two recently transplanted patients with bronchial stenoses treated using customised, biodegradable, polydioxanone stents (PDS).Methods: Two lung transplant recipients with cystic fibrosis were diagnosed with bronchus intermedius (Pt 1) and bilateral (left main bronchus and bronchus intermedius–Pt 2) stenoses in the first 3 months post LTx.Results: Pt 1 (46-year-old, male) was managed with 6 balloon dilatations and required 2 admissions for infections for Pseudomonas aeruginosa(PsA) before a PDS was inserted.FEV1 improved from 1.7L to >3L, with no admissions for infection since.Pt 2 (21 year old, female) positive for Burkholderia multivorans and PsA was initially managed with bilateral metal stents which were converted to PDS.There was significant reduction in granulation tissue caused by the metal stents after PDS insertion. Stents were absorbed within 8 weeks. Conclusions: PDS were safe and effective in restoring the patency of the airway in post LTx airway stenoses and were absorbed by the bronchial mucosa without granulation tissue formation or infections. More experience is required to assess their long term efficacy.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3496.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).